EGFL7 (Parsatuzumab Biosimilar) Recombinant Monoclonal Antibody

1. Data show that the expression level of epidermal growth factor-like domain 7 (EGFL7) and epidermal growth factor receptor (EGFR) in invasive growth hormone-producing pituitary adenomas (GHPA) was much higher than that of non-invasive GHPA. PMID: 29951953
2. EGFL7 was found to be a potential predictor for HCC survival and metastasis state. PMID: 29970668
3. Levels of both EGFL7 mRNA and EGFL7 protein are increased in blasts of patients with acute myeloid leukemia (AML) compared with normal bone marrow cells. High EGFL7 mRNA expression associates with lower complete remission rates, and shorter event-free and overall survival in older (age >/=60 y) and younger (age <60 y) patients with cytogenetically normal AML. PMID: 28533390
4. In conclusion, miR-126 could inhibit tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression PMID: 27611944
5. This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6 (mFOLFOX6) (folinic acid, 5-fluorouracil, and oxaliplatin) bevacizumab in patients with previously untreated metastatic colorectal cancer PMID: 28275117
6. Oncogenic activation of EGFRwt in GBM is likely maintained by a continuous EGFL7 autocrine flow line. PMID: 27725228
7. Egfl7 is thus an endogenous and constitutive repressor of blood vessel endothelial cell activation in normal and inflammatory conditions and participates in a loop of regulation of activation of these cells by pro-inflammatory cytokines. PMID: 27650497
8. Up-regulated MALAT1 promoted the invasion and metastasis of GC, and the increase of EGFL7 expression was a potential mechanism via altering its H3 histone acetylation level PMID: 27259812
9. These findings suggest that the stimulating effect of EGFL7-ESCs on fibroblast proliferation and migration may provide a useful strategy for wound healing. PMID: 27766530
10. A gene expression study was conducted to investigate the levels of Egfl7 and miRNA126-5p in human carotid artery atherosclerotic plaques PMID: 26799121
11. By regulating endothelial cell adhesion, EGFL7 plays a key role in the regulation of glioma angiogenesis. PMID: 26722408
12. The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF, suggests a possible important role of this angiogenic factor in a later oncogenic and infiltrative/metastatic phase. PMID: 26542361
13. EGFR mutational analysis is useful in the diagnosis of non-small-cell-lung cancer. PMID: 26288231
14. The aim of the present descriptive study was to analyse the intra-tumoural expressions of epidermal growth factor-like domain 7 (EGFL7) and microRNA-126 (miRNA-126) in primary tumours from patients with stage II-IV colorectal cancer. PMID: 25592646
15. EGFL7, OPN, and PGE2 may have a role in recurrence and metastasis of hepatocellular carcinoma PMID: 25730089
16. High EGFL7 expression promotes migration and Epithelial-Mesenchymal Transition in pancreatic Cancer. PMID: 25987088
17. Loss of EGFL7 expression is associated with Malignant Pleural Mesothelioma. PMID: 26504055
18. Data suggest that, in trophoblast cells, EGFL7 regulates cell migration and invasion/placentation by activating multiple signaling pathways via MAPK, PI3K (phosphatidylinositol 3-kinase), and NOTCH1 (translocation-associated notch protein 1). PMID: 25667199
19. EGFL7 may predict response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer PMID: 25140000
20. Endothelial cells control pancreatic cell fate at defined stages through EGFL7 signaling. PMID: 25601205
21. EGFL7 enhances EGFR-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PMID: 24945379
22. demonstrate significantly reduced Egfl7 expression in pre-eclampsia placentas, concurrent with a downregulation of Notch target genes PMID: 24751645
23. The loss of EGFL7 expression play a role in the development and progression of systemic sclerosis. PMID: 24286167
24. egfl7 is initially expressed in all endothelial cells and then is progressively restricted to veins and to their neighbouring capillaries. PMID: 24595089
25. EGFL7 promotes growth of Renal cell carcinoma by facilitating migration and tube formation of endothelial cells. These effects were produced by EGFL7-mediated focal adhesion kinase phosphorylation through combination with epidermal growth factor receptor. PMID: 24815445
26. malignant glioma cells and glioma vascular endothelial cells highly express VE-statin/Egfl7, which is significantly correlated with the degree of malignancy. PMID: 24696719
27. Egfl7 is significantly upregulated in human epithelial tumor tissues, suggesting Egfl7 to be a potential biomarker for human epithelial tumors, especially liver and breast cancer. PMID: 23558933
28. study provides clinical data indicating a relationship between miRNA-126 and the clinical outcome of metastatic colorectal cancer patients treated with chemotherapy combined with anti-VEGF-A, whereas the impact of EGFL7 is more speculative PMID: 23922111
29. Early-onset intrauterine growth restriction at 20-24 weeks' gestation is associated with higher values of EGFL7 expression in maternal plasma. PMID: 23280513
30. Egfl7 expression is thus associated with better prognosis factors and with the absence of lymph node invasion in human breast cancer lesions. PMID: 23404186
31. Data indicate that EGFL7 and integrin alphavbeta3 integrin colocalized in vesicular structures in uman umbilical vein endothelial cells (HUVECs). PMID: 23386126
32. Two angiogenesis-associated transcripts (Egfl7 and Acvrl1) showed lower expression in early-onset PE versus late-onset pre-eclampsia and versus gestational age-matched controls. PMID: 22013081
33. Human breast cancer lesions expressing high levels of Egfl7. PMID: 22037871
34. Studies indicate that Egfl7 controls blood vessel development by promoting endothelial cell migration and proliferation. PMID: 22160377
35. Heterogeneous methylation in the promoter region of EGFL7 was associated with cancer progression in non-small cell lung cancer. PMID: 22018271
36. miR-126 can downregulate EGFL7 expression at the protein level in ECV-304 cells. PMID: 20423846
37. Studies indicate that two biologically active miRNAs miR-126 and its complement miR-126*, which are encoded by intron 7 of the egfl7 gene, have been described to mediate vascular functions. PMID: 20953557
38. EGFL7 may be used as a predictive marker for glioma prognosis and as a potential therapeutic target for malignant glioma. PMID: 20213100
39. Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells. PMID: 20837907
40. miR-126 can inhibit proliferation of non-small cell lung cancer cells through one of its targets, EGFL7. PMID: 20034472
41. is the first identified inhibitor of mural cell migration specifically produced by endothelial cells. PMID: 14592969
42. Human EGFL7 may protect endothelial cell from hyperoxia-induced apoptosis by inhibition of mitochondria-dependent apoptosis pathway. PMID: 17934064
43. Intronic miRNAs from tissue-specific transcripts, or their natural absence, make cardinal contributions to cellular gene expression and phenotype. PMID: 18193184
44. The lack of association between expression of miRNA and its host gene EGFL7 suggests their regulation by independent stimuli in colon cancer. PMID: 18521848
45. Mature miR-126 can be generated from three different transcripts of EGFL7 with each one having its own promoter. PMID: 19116145
46. Egfl7 promotes metastasis of hepatocellular carcinoma (HCC) by enhancing cell motility through EGFR-dependent FAK phosphorylation. PMID: 19824075

Show More

Hide All

HGNC: 20594

OMIM: 608582

KEGG: hsa:51162

STRING: 9606.ENSP00000307843

UniGene: Hs.91481